Key facts
- Repair Biotechnologies’s last known valuation is $74.4M (Nov 2025).
- It has raised $22.9M across 6 recorded rounds; the latest was Early Stage VC ($5.3M) in Nov 2025.
- Notable investors include 100 Plus Capital, Bioverge Ventures, Emerging Longevity Ventures, Healthspan Capital, James Mellon — 14 tracked in total.
- Repair Biotechnologies has filed 8 Form Ds with the SEC since 2018, most recently Mar 2024 ($6.2M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Repair Biotechnologies
Funding rounds
6 roundsAbout Repair Biotechnologies
Operator of a preclinical biotechnology company intended to develop drugs for cholesterol and aging-related diseases. The company's cholesterol-degrading platform (CDP) technology is aimed at reversing atherosclerosis, familial hypercholesterolemia, and other conditions in which excess or modified cholesterol drives pathology, enabling healthcare providers to rapidly and dramatically reduce atherosclerotic plaque in arteries, the cause of stroke, heart attack, and other cardiovascular diseases.
- Sector
- Healthcare
- HQ
- Syracuse, NY, United States
- Founded
- 2018
- Employees
- 10
- Website
- repairbiotechnologies.com/
- Ownership
- Privately Held (backing)
Repair Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Repair Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Repair Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.